Related references
Note: Only part of the references are listed.A prospective multicenter study of sirolimus for complicated vascular anomalies
Yi Ji et al.
JOURNAL OF VASCULAR SURGERY (2021)
Patients with Congenital Low-Flow Vascular Malformation Treated with Low Dose Sirolimus
Veroniek E. M. Harbers et al.
ADVANCES IN THERAPY (2021)
Efficacy and safety of sirolimus in the treatment of vascular anomalies: A systematic review
Cristiana Freixo et al.
JOURNAL OF VASCULAR SURGERY (2020)
Monitoring Arteriovenous Malformation Response to Genotype-Targeted Therapy
Emily A. Edwards et al.
PEDIATRICS (2020)
Oral Sirolimus: An Option in the Management of Neonates with Life-Threatening Upper Airway Lymphatic Malformations
Paloma Triana et al.
LYMPHATIC RESEARCH AND BIOLOGY (2019)
Generalized lymphatic anomaly successfully treated with long-term, low-dose sirolimus
Veronika Dvorakova et al.
PEDIATRIC DERMATOLOGY (2018)
Pneumocystis Jirovecii Pneumonia During Sirolimus Therapy for Kaposiform Hemangioendothelioma
Thomas B. Russell et al.
PEDIATRICS (2018)
Sirolimus is efficacious in treatment for extensive and/or complex slow-flow vascular malformations: a monocentric prospective phase II study
Jennifer Hammer et al.
ORPHANET JOURNAL OF RARE DISEASES (2018)
Somatic MAP2K1 Mutations Are Associated with Extracranial Arteriovenous Malformation
Javier A. Couto et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2017)
Efficacy and Safety of Mammalian Target of Rapamycin Inhibitors in Vascular Anomalies: A Systematic Review
Marion Nadal et al.
ACTA DERMATO-VENEREOLOGICA (2016)
Evidence-Based Management of Vascular Malformations
Patrick Morgan et al.
FACIAL PLASTIC SURGERY (2016)
Efficacy and Safety of Sirolimus in the Treatment of Complicated Vascular Anomalies
Denise M. Adams et al.
PEDIATRICS (2016)
Sirolimus and everolimus in kidney transplantation
Dirk Jan A. R. Moes et al.
DRUG DISCOVERY TODAY (2015)
Treatment of Childhood Kaposiform Hemangioendothelioma With Sirolimus
Julie Blatt et al.
PEDIATRIC BLOOD & CANCER (2010)
All roads lead to mTOR - Integrating inflammation and tumor angiogenesis
Dung-Fang Lee et al.
CELL CYCLE (2007)
Vascular malformations - Part I
Maria C. Garzon et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2007)
MTOR-targeted therapy of cancer with rapamycin derivatives
S Vignot et al.
ANNALS OF ONCOLOGY (2005)
mTOR, translational control and human disease
AR Tee et al.
SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY (2005)
Dosing of rapamycin is critical to achieve an optimal antiangiogenic effect against cancer
M Guba et al.
TRANSPLANT INTERNATIONAL (2005)
Pharmacokinetics and safety of single oral doses of sirolimus (rapamycin) in healthy male volunteers
C Brattström et al.
THERAPEUTIC DRUG MONITORING (2000)
Share Paper
